Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: Metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 5, 2009 (14 weeks)
Comparative Period: March 30, 2008 (13 weeks)
Business Overview: A leading provider of technology, services, and solutions for diagnostics, research, environmental monitoring, safety, security, and laboratory services. The company realigned its operations into two strategic segments effective for fiscal year 2009: Human Health and Environmental Health.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2009 | Q1 2008 |
|---|---|---|
| Sales | $431,574 | $458,720 |
| Gross Margin | 43.6% | 41.9% |
| Operating Income (Continuing Ops) | $25,745 | $33,433 |
| Net Income (Continuing Ops) | $15,061 | $20,739 |
| Net Income (Total) | $10,559 | $20,138 |
| Diluted EPS (Total) | $0.09 | $0.17 |
| Cash from Operating Activities | $14,945 | $15,605 |
| Cash and Cash Equivalents (End of Period) | $162,049 | $185,262 |
| Long-Term Debt | $544,030 | $509,040 |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 6% ($27.1 million) year-over-year. This was driven by a 2% decline in Human Health sales (due to reduced demand for medical imaging products) and a 9% decline in Environmental Health sales (due to private testing labs reducing capital purchases).
- Restructuring Charges: The company incurred $7.8 million in restructuring and lease charges in Q1 2009, compared to none in Q1 2008. These charges were taken to reduce resources in anticipation of decreasing demand.
- Discontinued Operations: Net income was significantly impacted by a $2.9 million loss from discontinued operations and a $1.6 million loss on the disposition of discontinued operations (primarily ViaCyte and Cellular Therapy Technology businesses).
- Margin Expansion: Despite lower sales, gross margin expanded by 167 basis points to 43.6%, driven by productivity improvements and a favorable product mix.
- Acquisitions: The company acquired Opto Technology Inc. in January 2009 (approx. $20.6 million cash plus contingent consideration) and Analytica of Branford, Inc. in May 2009 (approx. $24.0 million cash).
Guidance, Outlook, and Risks
- Outlook: Management expects the immediate cost savings from the Q1 2009 restructuring plan to offset the decline in revenue. They anticipate growth in the research market due to government stimulus packages and in the newborn screening business as healthcare cost pressures increase.
- Liquidity: The company maintains a $650 million senior unsecured revolving credit facility with $242 million available as of April 5, 2009. Cash and cash equivalents stood at $162 million.
- Capital Allocation: The company repurchased 1 million shares of common stock for $14.2 million under its repurchase program. A quarterly dividend of $0.07 per share was declared.
- Risks:
- Economic Conditions: Continued global economic contraction and tight credit markets are adversely affecting customer capital spending.
- Legal Proceedings: Ongoing litigation includes patent disputes with Enzo Biochem (stayed pending appeal) and PharmaStem (patents cancelled by PTO, dismissal sought).
- Environmental: Accrued $4.4 million for environmental remediation costs.
- Pension Funding: Potential requirement to fund pension plans with approximately $18 million by fiscal year 2010.
Investor Verification Checklist
- Verify the impact of the $7.8 million restructuring charge on future operating cash flows and cost savings realization.
- Monitor the progress of the divestiture of Photonics and Photoflash businesses and the shutdown of specific instrument businesses.
- Assess the integration and financial contribution of the Opto Technology and Analytica acquisitions.
- Review the status of the Enzo Biochem litigation and potential financial exposure.
- Track the company's ability to maintain compliance with debt covenants (debt-to-capital ratios) amidst economic volatility.
- Confirm the timeline and cost of the anticipated $18 million pension plan contribution.